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Abstract: Chemotherapy-induced bone damage is a frequent side effect which causes 
diminished bone mineral density and fracture in childhood cancer sufferers and survivors. 
The intensified use of anti-metabolite methotrexate (MTX) and other cytotoxic drugs has led 
to the need for a mechanistic understanding of chemotherapy-induced bone loss and for the 
development of protective treatments. Using a young rat MTX-induced bone loss model, we 
investigated potential bone protective effects of phytoestrogen genistein. Oral gavages of 
genistein (20 mg/kg) were administered daily, for seven days before, five days during, and 
three days after five once-daily injections (sc) of MTX (0.75 mg/kg). MTX treatment 
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reduced body weight gain and tibial metaphyseal trabecular bone volume (p < 0.001), 
increased osteoclast density on the trabecular bone surface (p < 0.05), and increased the  
bone marrow adipocyte number in lower metaphyseal bone (p < 0.001). Genistein 
supplementation preserved body weight gain (p < 0.05) and inhibited ex vivo osteoclast 
formation of bone marrow cells from MTX-treated rats (p < 0.001). However, MTX-induced 
changes in bone volume, trabecular architecture, metaphyseal mRNA expression of  
pro-osteoclastogenic cytokines, and marrow adiposity were not significantly affected  
by the co-administration of genistein. This study suggests that genistein may suppress  
MTX-induced osteoclastogenesis; however, further studies are required to examine its 
potential in protecting against MTX chemotherapy-induced bone damage. 
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1. Introduction 
Chemotherapy is known to cause significant adverse effects in the bone, notably bone growth arrest 
and/or diminished bone mineral density (BMD) in growing or adult bones [1–4]. Whilst there is evidence 
to suggest some changes may be acute, the use of chemotherapy to treat childhood malignancies is 
strongly associated with a persisting low BMD long after the cessation of treatment [4,5]. Chemotherapy 
of childhood cancers is known to negatively impact a crucial window of bone growth and bone  
mass accrual [6]. As a result, failure to reach an optimal peak BMD during puberty can lead to a  
lower-than-average adult BMD, an outcome linked to an increased risk of fracture [1,7–11]. 
Methotrexate (MTX) is an anti-metabolite chemotherapeutic which inhibits the utilisation of folate 
during de novo purine and thymidine synthesis, in turn disrupting DNA/RNA synthesis and cell 
replication [12]. Therapeutically, MTX is a common choice for the treatment of childhood cancers such 
as acute lymphoblastic leukaemia (ALL) and, consistent with other chemotherapeutics, has been shown 
to induce bone growth arrest and diminished BMD in these patients [2,10,13–15] as well as in long-term 
follow up in survivors [16,17]. As a result of its common use, treatment success, and associated  
bone-related side effects, MTX has become an increasingly studied chemotherapeutic in relation to 
understanding the underlying mechanisms of and preventing the associated bone defects. 
Some previous studies have shown a link between MTX-induced bone loss and alterations to the bone 
remodeling balance and environment following MTX administration. Altered levels of serum bone 
turnover markers in ALL patients receiving MTX indicated increased bone resorption (carried out  
by osteoclasts) and, conversely, diminished bone synthesis (carried out by osteoblasts) [13,15]. 
Consistently, these effects are reflected in experimental studies examining the effect of MTX in long 
bones of rodents [18,19]. Supportively, the administration of MTX acutely affects both the densities of 
the remodeling cells (diminished osteoblast numbers but increased osteoclast presence on trabecular 
bone surfaces) [18,20–22]. More recently, this has been shown to be related to the altered differentiation 
potential of the bone cells from their respective precursors within the bone marrow. A switch in lineage 
determination from the remaining common bone marrow stromal precursor cells has been observed, 
favouring adipocyte formation rather than the formation of osteoblasts, a change which leads to the 
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increased presence of fat (adiposity) within bone marrow [23,24]. In addition, increased osteoclast 
formation from the bone marrow cells following MTX administration has been linked to the onset of a 
local and systemic pro-inflammatory environment with the elevated expression of pro-osteoclastogenic 
cytokines, which are capable of inducing osteoclast formation both in vivo and ex vivo [25]. Thus, MTX 
can induce a reduction in bone volume via disruption to normal bone remodeling with reduced bone 
formation but increased resorption. 
Currently, there is no accepted specific supplementary treatment aimed at reducing or preventing 
MTX chemotherapy-induced bone damage. Traditional anti-resorptive therapies such as the bisphosphonates 
(Alendronate) and receptor activator of NF-κB ligand (RANKL) antibodies (Denosumab) may offer 
bone protective effects against cancellous and spongy bone loss caused by the malignancy and/or 
therapies, including hormone/androgen therapy (HRT), radiotherapy, and chemotherapy [26]. However, 
whilst they are the gold standard for osteoporosis management, their use for preventing cancer or 
therapy-induced bone loss is associated with significant complications such as osteonecrosis of the jaw 
and/or disruption of normal bone remodeling [27,28]. In this respect, alternative therapies devoid of 
significant side effects or contraindications may be appealing. 
Currently, there have been some recent rodent experimental studies examining potential benefits of 
natural substances in attenuating MTX adverse side effects, including those of folinic acid (folate 
analogue) [29] and fish oil [30]. Recent studies have also shown potential benefits of genistein,  
a phytoestrogen with known bone-sparing properties. Whilst there is some conjecture about the bone 
protective effects of genistein within post-menopausal women [31], there is a considerable amount of 
evidence for its benefit [32]. One of the first observations of the potential bone protective effect of 
genistein was observed in Asian populations of post-menopausal women where it was reported that  
those who consume diets rich in soy suffered fewer fractures than Caucasian women [32], an outcome 
attributed to an increase in BMD [33,34]. Consistently, genistein has demonstrated positive anabolic 
effects upon BMD in ovariectomised (OVX) rodents where its supplementation promotes bone 
formation and inhibits the bone loss associated with estrogen depletion [35–37]. Genistein has been 
shown to be able to promote osteogenesis and inhibit osteoclastogenesis, thus positively affecting the 
bone remodeling both in vitro and in vivo [38]. 
With our improved understanding of the mechanisms associated with MTX-induced bone loss, the 
current study investigated the effects of genistein supplementation upon MTX-induced changes in bone 
volume and the bone remodeling cells with tibial metaphysis (the region with the most active bone 
remodeling) at a critical time-point (day nine following the first of five consecutive once-daily MTX 
injections) when pronounced bone damage is known to occur [22,25]. 
2. Results 
2.1. Effects on Body Weight Changes 
Consistent with previous studies, five daily injections of MTX caused considerable attenuation of 
body weight gain (Figure 1) with MTX-treated rats gaining, on average, 46.2 ± 2.5 g whilst control rats 
gained 61.9 ± 1.1 g from day one (D1) to D9 (p < 0.01) (Figure 1B). Overall, genistein oral gavage  
(15 consecutive days, including during the five days of MTX administration) was well-tolerated with no 
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observable changes in appearance or behavior of the rats in the genistein alone group. Whilst the 
genistein plus MTX group (55.4 ± 1.2 g from D1 to D9) did not achieve the same total weight gain as 
saline control rats (p > 0.05), the weight increase was significantly greater than in those treated with 
MTX alone (p < 0.05) (Figure 1B). 
 
Figure 1. Effects of methotrexate (MTX) with/or without genistein on body weight gain. 
(A) Representative graph of weight accumulation over the period of treatment illustrating 
that MTX treatment (open circles, dashed line) slowed body weight gain, whilst the MTX 
and genistein combination (Gen/MTX, open square, dashed line) recovered their weight by 
the end of the trial; (B) Total body weight gained over the period of MTX administration 
until specimen collection. MTX significantly reduced weight accrual when compared to 
control group (** p < 0.01) or to the Gen alone group (δ p < 0.001), and Gen supplementation 
(Gen/MTX) significantly attenuated the weight accrual suppression when compared to MTX 
alone group (# p < 0.05) (n = 6). 
2.2. Effects on Bone Volume and Trabecular Structure and Bone Turnover 
Effects of MTX and/or genistein treatments upon tibial bone histomorphometry were assessed in  
the secondary spongiosa of the tibial metaphysis (Figure 2), a region shown previously to have bone  
loss after MTX treatment [22]. Trabecular bone volume (BV/TV%) was significantly reduced in MTX 
alone rats (p < 0.001) and in MTX plus genistein-treated rats (p < 0.01) when compared to saline  
controls (Figure 2A,B vs. Figure 2C,E). No difference was observed between control and genistein  
alone rats (Figure 2A vs. Figure 2B,E). The reduction in bone volume was not as severe in the case of 
MTX co-administered with genistein, although it was still significantly less than the control (p < 0.01). 
The mean bone volume for controls was 31.91%, whilst the mean value of the MTX and genistein 
combination (Gen/MTX) rats was higher than that of MTX treated rats, 25.16% vs. 21.71%, respectively, 
and the effect of combined treatment did not result in a significant difference between the latter two 
groups (p = 0.1405). 
As trabecular bone mass is related to bone architecture, the trabecular number, thickness, and spacing 
were also examined. No significant differences were observed between any groups with regards to 
spacing and thickness. However, compared to the genistein alone group, MTX treatment significantly 
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reduced the number of trabeculae in the metaphysis (p < 0.01) (Figure 2B vs. Figure 2C,F). Co-treatment 
of MTX with genistein was not significantly different from MTX alone in regard to affecting trabecular 
number, thickness, or spacing. 
As an assessment of the treatment impact on bone formation, the serum concentrations of bone 
formation marker alkaline phosphatase (ALP) were measured and were shown to be significantly 
reduced following MTX treatment when compared to the control (Figure 2G). However, there were  
no differences between other groups, and genistein in combination with MTX did not rescue this  
MTX effect. 
 
Figure 2. MTX reduced metaphyseal trabecular bone volume and serum levels of alkaline 
phosphatase (ALP) compared to the control. (A–D) Representative images (20×) of 
haematoxylin and eosin (H&E) and tartrate-resistant alkaline phosphatase (TRAP, a marker 
for osteoclasts)-stained sections for control, MTX-, genistein (Gen)-, and Gen/MTX-treated 
groups, respectively. Pink staining indicates osteoclasts (white arrows) which line the 
trabecular bone (Tb) surface; (E) Quantification of bone volume measured as the percentage 
of total tissue area occupied by trabecular bone (BV/TV%); (F) Quantification of the number 
of trabeculae spanning the width of the secondary spongiosa (Tb.#/mm); (G) Serum analysis 
of ALP levels. * p < 0.05, ** p < 0.01 and *** p < 0.001 vs. control; # represents a statistical 
difference between treatment groups with p < 0.01 (n = 6). 
2.3. Effects on Densities of Bone Modelling/Remodeling Cells within the Metaphysis 
To assess if genistein had positive effects on bone modelling that may protect against MTX-induced 
bone damage, the respective densities of osteoblasts and osteoclasts within the metaphysis were  
assessed (Figure 3). The density of osteoblasts (black arrows) was consistent for all treatment groups  
(Figure 3A–E). However, the numbers of osteoclasts, identified as large, tartrate-resistant alkaline 
phosphatase (TRAP)+, and multinucleated cells lining the trabecular surface (white arrows Figure 3A–D), 
were greatest in MTX-treated rats, and these were significantly greater than those treated with genistein 
alone (p < 0.05) (Figure 3B,F vs. Figure 3C). Co-treatment (Gen/MTX) did not significantly attenuate 
this effect despite the small trend to yield fewer osteoclasts/mm2 than MTX alone (86.9 ± 8.7 and  
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104 ± 9.4, respectively; p = 0.43). Noticeably, MTX treatment did not significantly increase the number 
of osteoclasts lining the trabecular surface when compared to control animals (p = 0.104). 
 
Figure 3. MTX treatment increased the density of bone-resorbing osteoclasts and genistein 
had no significant effect on densities of the remodeling cells. (A–D) Representative images 
(40×) of H&E-stained tibial metaphysis sections from a control, genistein (Gen)-, MTX-, or 
genistein + MTX (Gen/MTX)-treated rat, respectively, which have been counterstained with 
TRAP for osteoclast identification (white arrows: osteoclasts or OC; black arrows: 
osteoblasts or OB); (E) Quantification of osteoblast density (OB/mm2) within the secondary 
spongiosa region of the metaphysis; (F) Quantification of osteoclast density (OC/mm2) 
identified as multinucleated (≥3 nuclei) TRAP+ cells (white arrows). n = 6, # p < 0.05 
between MTX and Gen groups. 
2.4. Effects on ex Vivo Osteoclastogenesis 
Genistein is known to reduce bone resorption in vivo [39] and also suppress osteoclast formation  
in vitro [37,40]. Here, the effect of genistein treatment in vivo upon the potential of the bone marrow 
cells of treated rats to form mature osteoclasts ex vivo was examined in macrophage colony stimulating 
factor (M-CSF) and RANKL-induced osteoclastogenesis cultures (Figure 4). Osteoclasts (black arrows), 
identified via light microscopy as large TRAP+ multinucleated (≥3 nuclei) cells, were apparent in 
cultures from all treatment groups (Figure 4A–C) but were present in significantly greater numbers in 
cultures of MTX alone-treated rats (p < 0.001) (Figure 4A vs. Figure 4B,D). Noticeably, the co-treatment 
of MTX with genistein significantly suppressed the effect of MTX-induced osteoclastogenesis  
(5.5 ± 0.4 vs. 36.3 ± 4.2 osteoclasts/mm2, respectively, p < 0.001 between the MTX plus genistein group 
and the MTX alone group) (Figure 4C,D). 




Figure 4. Co-treatment with genistein (Gen) significantly suppressed MTX-induced  
ex vivo osteoclast formation. (A–C) Representative images (20×) of osteoclasts differentiated 
in the presence of macrophage colony stimulating factor (M-CSF) and receptor activator of 
NF-κB ligand (RANKL) from bone marrow mononuclear cells isolated from control,  
MTX-, and Gen + MTX-treated rats, respectively. Cells were subsequently stained with 
TRAP to identify osteoclasts; (D) Osteoclasts were identified as large, TRAP+, and 
multinucleated cells (≥3 nuclei) (black arrows in panels A–C) and quantified as 
osteoclasts/mm2 of culture dish. n = 6, *** p < 0.001 vs. control. 
2.5. Effects on Expression of Osteoclastogenesis-Related Genes in Metaphyseal Bone 
To examine if genistein offered protection against MTX-induced damage by modulating the 
expression of factors regulating osteoclast formation and activity, the mRNA expression in metaphysis 
bone was analysed for osteoclastogenesis regulatory factors, including RANKL and osteoprotogerin 
(OPG) as well as pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-α), 
interleukin-1 (IL-1), and IL-6. Following MTX administration, both the critical osteoclastogenic factor 
RANKL and inhibitor OPG (RANKL decoy receptor) demonstrated significant elevation in mRNA 
expression (p < 0.05 and p < 0.01 vs. control); however, their expression was not affected by other 
treatments (Figure 5A,B). The ratio of expression of RANKL to OPG (RANKL:OPG) was unaffected 
by any treatments, despite the obvious changes in individual expression levels (Figure 5C). Since IL-6, 
IL-1β, and TNF-α are known to augment osteoclast formation and activity, their relative expression 
levels were also analysed in the metaphysis bone. MTX alone induced an increase in IL-6 (p < 0.01 vs. 
control) and IL-1β (p < 0.05) expression (Figure 5D,E) and tended to increase TNF-α (p = 0.0553) 
expression (Figure 5E). Noticeably, both MTX alone and MTX plus genistein groups displayed greater 
expression of IL-1β when compared to the genistein alone group (p < 0.05) (Figure 5E). 




Figure 5. MTX administration increased mRNA expression of receptor activator of NF-κB 
ligand (RANKL), osteoprotogerin (OPG), interleukin-6 (IL-6), and IL-1β in the metaphysis 
bone compared to control rats. (A,B) Quantitative RT-PCR of osteoclastogenesis regulators 
RANKL and OPG, respectively, within the metaphysis; (C) Ratio of relative mRNA 
expression of RANKL to OPG; (D–F) Quantitative RT-PCR of pro-inflammatory cytokines 
IL-6, IL-1β, and tumor necrosis factor-alpha (TNF-α), respectively. n = 6, * p < 0.05 and  
** p < 0.01 vs. control; # p < 0.01 between Gen and MTX alone groups, and δ p < 0.05 
between Gen alone and Gen/MTX groups. 
2.6. Bone Marrow Adiposity 
Adipocytes, which are found interspersed within marrow cells in the lower metaphysis and diaphysis 
of long bones, have been shown to be sensitive to MTX chemotherapy and thus were examined here 
(Figure 6). MTX significantly increased the density of adipocytes within the marrow cavity of the lower 
metaphysis when compared to the control (p < 0.01) and genistein alone (p < 0.05) groups (Figure 6A,B 
vs. Figure 6C,E). Whilst the bones of rats with the combination treatment of genistein with MTX 
(Gen/MTX) displayed fewer adipocytes, this was not significantly lower than those arising from MTX 
alone (Figure 6C vs. Figure 6D,E). Since an increase in the expression of adipogenic transcription  
factor CCAAT/enhanced binding protein-α (C/EBPα) mRNA expression is associated with initiation of 
adipocyte formation, its relative expression level within the metaphysis was also examined to see if 
genistein affected adipogenesis following MTX treatment. MTX alone-treated animals tended to exhibit 
a higher expression level compared to saline controls (control vs. MTX, p = 0.9064), whilst the 
Gen/MTX combination treatment tended to attenuate MTX-induced C/EBP-α expression (MTX vs. 
Gen/MTX, p = 0.9275) (Figure 6F). 




Figure 6. Changes in adipocyte density within the lower secondary spongiosa of the tibia in 
rats following various treatments. (A–D) Representative photographs (20×) of sections 
stained with H&E for control, genistein (Gen), MTX, and Gen + MTX groups, respectively. 
Adipocytes (white arrows) are easily identified as empty spaces within the marrow cavity 
which are encased by a membrane; (E) The density of adipocytes was quantified as the 
number of adipocytes/mm2 of marrow cavity excluding bone area; (F) Adipogenesis 
transcription factor CCAAT/enhanced binding protein-α (C/EBPα) relative mRNA 
expression as quantified via RT-PCR. n = 6, ** p < 0.01 vs. control, and # p < 0.05 between 
Gen and MTX groups. 
3. Discussion 
The use of MTX as a chemotherapeutic commonly causes bone-related defects including bone growth 
arrest, disruption of bone remodeling, diminished BMD, and an increased likelihood of fracture. Despite 
these significant and ongoing side effects, there are currently no specific therapies employed in an effort 
to prevent or attenuate their onset. Based on our understanding of the effect of MTX upon the bone 
remodeling cells, and the mechanisms through which this occurs, genistein became a compound of 
interest for therapeutic exploration. In a number of studies in vivo, genistein has been reported to promote 
bone mass preservation via an increase in bone formation and a decrease in bone resorption [33,34,41,42]. 
This current study demonstrates that genistein had minimal protective effect upon MTX-induced damage 
in bone volume and structure, densities of osteoblasts and osteoclasts, and bone marrow adiposity. 
However, genistein did afford significant protection against MTX-induced osteoclastogenesis, which is 
a prominent mechanism mediating MTX-induced bone loss [25]. 
As this is one of the first cases of genistein being tested as an adjuvant therapy during MTX 
administration, we selected the dose of genistein at 20 mg/kg based on those shown to have positive 
effects in OVX bone loss models (10–45 mg/kg/day) [35–37]. Higher doses of up to 500 mg/kg/day 
have been associated with osteopetrosis and alteration to the gonadal function in both females and  
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males [43]. Of note, our chosen dose of 20 mg/kg/day is well below the minimum adverse effect level 
associated with these negative changes [43], and we found the administration of genistein at this dose to 
be well tolerated in rats. However, the treatment regimen of the current study is a potential limitation 
where a singular daily oral gavage may not be effective in providing beneficial effects in bone, as the 
serum levels of genistein achieved via this delivery may not be sufficient to cause significant effects  
and those levels may not reflect those achievable as a dietary supplement [44]. Nevertheless, the 
administration of genistein with this dosing regimen appeared to have improved the health of rats  
during the administration of MTX as observed from the rats’ general well-being, and the extents of  
MTX-induced gastrointestinal side effects and bone weight gain during the treatment period. Previously, 
we have noted that rats receiving chemotherapeutic doses of MTX suffer from gastrointestinal irritation 
and malnourishment [45,46], an effect evident in MTX alone-treated rats in this study. Using weight 
gain as a crude indicator of nutritional health and overall growth, we found that MTX-treated rats 
supplemented with genistein regained weight quicker than their MTX alone counterparts and achieved 
a similar total weight gain as control rats by the end of the study. Collectively, this study suggests that 
genistein may help to relieve or aid in the repair of gut mucosal irritation caused by MTX, and that it 
may be a source of secondary benefit on bone health, considering that nutrition and mobility play 
significant roles in bone mass accrual and maintenance, especially during this period of bone development. 
Consistent with our previous studies [22,25], MTX caused a reduction in the total bone volume 
measured within the secondary spongiosa; however, whilst this is usually associated with altered bone 
architecture, in this case MTX did not alter the number, thickness, or spacing of trabeculae. Genistein 
treatment alone, which has been shown to alter bone mass and architecture in some bone loss model 
studies [36,47,48], did not affect the bone volume or number of trabeculae within the secondary 
spongiosa in saline control-treated normal rats. Similarly, when given in combination with MTX, it did 
not significantly attenuate MTX-induced changes. Overall, the effect on bone morphometry of genistein 
at this dose, in combination with MTX treatment, is difficult to conclude in this particular study using 
this acute treatment setting. In order to truly assess genistein’s potential during MTX chemotherapy, 
more studies are required with both acute and long-term MTX treatment models with different doses. 
Typically, negative changes in the densities of the bone remodeling cells within the metaphysis 
accompany a decrease in the bone volume; hence, the suitability of genistein in preventing this was 
assessed here. Consistently, with bone morphology in this study, MTX did not significantly alter the 
densities of the bone remodeling cells although MTX treatment appeared to increase osteoclast density 
on bone surfaces. Consistent with genistein’s effects upon bone volume and architecture, treatment with 
genistein alone or in combination with MTX did not cause significant changes in osteoclast or osteoblast 
densities. Interestingly, whilst the genistein alone group was not different to controls in osteoclast 
density, there were significantly fewer osteoclasts in the genistein alone group compared to the MTX 
alone group. 
A recent development in the understanding of MTX chemotherapy-induced bone loss has highlighted 
the role of osteoclasts in this process. It was shown that an increase in osteoclast density within the 
metaphysis is associated with an increase in the bone marrow's potential to form osteoclasts [22,25].  
As expected, MTX treatment increased the osteoclastogenic potential of the bone marrow precursor  
cells ex vivo. Previously, this MTX-induced osteoclastogenesis has been linked with changes in 
osteoclastogenic cytokine gene expression within the metaphysis as well as with an increase in serum 
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concentration [25], an observation that was also seen in patients treated with chemotherapy as well as  
in vitro [49,50]. In the current study, MTX increased the mRNA expression for IL-1β and IL-6 and also 
appeared to induce TNF-α (p = 0.0552) despite the lack of effect in modulating the RANKL/OPG 
expression ratio. In this study, genistein’s most notable protective effect against MTX-induced changes 
within the bone was found to center on an ability to significantly inhibit the MTX-induced increase  
in bone marrow osteoclastogenic potential. Although genistein supplementation displayed trends of 
suppressing MTX-induced cytokine expression, statistically, none of these changes are significant. 
However, the MTX/genistein combination treatment was demonstrated to have a significant and 
dramatic effect upon ex vivo osteoclast formation from bone marrow cells of treated rats. This 
suppressing effect ex vivo appears to be consistent with the effect of the combination treatment in  
non-significantly lowering the MTX-induced osteoclast density on bone surface in vivo. Previously, 
genistein has been shown to attenuate osteoclast formation and activity in vitro [40,51], and genistein 
has been reported to inhibit inflammation-induced osteoclast formation and activity and bone loss 
through modulating the expression of pro-osteoclastogenic cytokines TNF-α, IL-1, and IL-6 [52,53]. 
Further studies will be required to study the potential effects and action mechanisms of genistein in 
modulating osteoclast formation and activity in cancer chemotherapy bone loss settings. 
Apart from analyzing treatment effects on osteoclastogenesis and the presence of bone-resorbing 
osteoclasts, the current study has also examined treatment effects on osteoblast density and bone 
formation. We found that whilst MTX treatment did not significantly decrease osteoblast density (data 
not shown), it caused a reduction in bone formation as assessed by serum ALP levels. This observation 
is consistent with previous findings that MTX reduces the osteogenic potential of bone marrow stromal 
progenitor cells [23,24]. We also found that whilst genistein supplementation did not significantly 
prevent this decrease in ALP levels, it had a moderate but statistically non-significant effect in 
attenuating a MTX-induced decrease in this bone formation marker. Genistein is known to have  
pro-osteoblastic effects in vitro and osteoblasts treated with genistein increase their rate of 
osteogenesis/mineralization and the expression of bone protein osteocalcin [54,55]. Consistently, 
genistein treatment delayed or prevented bone loss in the OVX model of osteoporosis [56,57]. Further 
studies with various doses and treatment protocols are required to investigate the potential  
pro-osteogenic effects of genistein in MTX chemotherapy models. 
In some previous studies, the MTX-induced decrease in osteogenic potential was shown to be due to 
changes in the lineage determination of bone marrow stromal cell precursor cells, whereby adipocytes 
are formed in preference over osteoblasts [23,24]. One aspect of this includes an increased expression 
of the early adipogenic regulator C/EBP-α in MTX-treated rat stromal cells as we also showed here. 
Consistent with this and other previous studies, MTX caused an increase in adipocyte numbers within 
the bone marrow cavity [23]. Noticeably, whilst MTX alone-treated rats had significantly more marrow 
adipocytes than rats receiving genistein alone, genistein did not reduce adipocyte numbers significantly 
in MTX-treated rats, even though the marrow cavity appeared healthier as a result. Consistently, the 
expression of C/EBP-α was highest in the MTX-treated animals and the co-administration of genistein 
seemed to attenuate this increase, though the effect was statistically non-significant. Of note, genistein 
at a higher dose has been demonstrated to reduce adipogenic deposition in rodents previously; 
importantly, whilst 20 mg/kg dose only demonstrated a trend, higher doses caused significant  
effects [58], suggesting that an increased genistein dose may show more significant effects in attenuating 
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MTX-induced adiposity. Hence, it is apparent that whilst MTX has been consistently shown to cause 
bone marrow adiposity, further studies are required to examine the potential protective effects of 
genistein at different doses or treatment protocols against MTX-induced bone marrow fat accumulation. 
Although some experimental studies have reported minimal effects of genistein in OVX models of 
osteoporosis [59,60], and a clinical study has reported evidence of post-menopausal women failing to 
receive benefits of genistein [31], the potential benefit of genistein supplementation in protecting bone 
has been demonstrated in many OVX bone loss model studies [36,39,48] and in some human dietary 
studies [32], and its pro-osteogenic and anti-osteoclastogenic actions have been observed in various  
in vitro and in vivo studies [38]. Due to its ability in positively modulate bone remodeling, the current 
study evaluated the potential of genistein as a bone protective agent in the setting of childhood 
chemotherapy-induced bone loss. In this study with this acute MTX treatment model (mimicking the 
acute intensive induction phase of clinical MTX treatment for the major childhood cancer acute 
lymphoblastic leukemia), genistein supplementation was demonstrated to have some promise  
in a number of areas, including protection of the general well-being and growth of the animals and, 
importantly, in attenuating MTX-induced osteoclast formation from the bone marrow cells. 
Experimentally and in the clinic, MTX treatment has been consistently demonstrated to cause bone loss 
due to increased bone resorption and reduced bone formation. The observed ability of genistein to 
suppress MTX-induced osteoclastogenesis may have significant consequences on bone health and 
warrants further studies. While the current study showed that genistein supplementation was not able to 
significantly attenuate some parameters of MTX-induced adverse effects in bone (including changes in 
bone volume, serum ALP level, bone marrow adiposity, and gene expression as outlined above), data 
from the current study has provided some information which will be useful to further investigate the 
potential effects and action mechanisms of genistein in protecting bone in chemotherapy-induced bone 
loss models, including studies with larger cohorts, across a variety of doses considering potential 
concerns on its usage safety [41,61], incorporating measures for monitoring its serum levels, considering 
potential differences of its metabolism between rodents and humans [62], and in acute and  
chronic treatment models (including both the acute induction phase and maintenance phase of MTX 
treatment) [20]. 
4. Experimental Section 
4.1. Animal Trials with Methotrexate (MTX) and/or Genistein Administration 
Male Sprague-Dawley rats aged six weeks were randomly divided into four treatment groups  
(n = 6): control, genistein, MTX, and MTX + genistein (referred to as “gen/MTX”). Over the course of 
the experiment, all rats were housed in standard conditions with 12 h light-dark cycles and were provided 
standard rat chow and water ad lib. All procedures were approved (project #05-08, approved on  
28 March 2008) by SA Pathology Animal Ethics Committee, South Australia. 
Irrespective of their allocated treatment groups, all rats received daily subcutaneous injections of 
MTX or saline, in combination with preventative, concurrent, and continuing oral gavages of genistein 
or vehicle. Injections of MTX were administered daily for five consecutive days at a dose of 0.75 mg/kg 
as previously described [22,25]. Genistein at 20 mg/kg or vehicle was administered once daily via oral 
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gavage throughout the trial: for seven days prior to the first MTX injection, for five days concurrently 
with MTX administration, and for three days after the final MTX administration. Control groups 
received injections of saline and oral gavages of vehicle, MTX rats received MTX and vehicle, genistein 
rats received saline and genistein oral gavages, and finally the gen/MTX animals received both MTX 
injections and oral gavages of genistein. Oral gavages were prepared by first solubilizing genistein 
(Bonistein™, DSM Nutritional Products, Kaiseraugst, Switzerland) in 100% Dimethyl-sulfoxide (DMSO) 
at 100 mg/mL. This was further diluted in a solution of 50% Tragacanth in water to a final concentration 
of 5 mg/mL. The final volume of oral gavage to be administered (between 0.5 and 2.5 mL total) depended 
on rat body weights. Bone specimens were collected on day nine following the first MTX dosing. 
4.2. Histological Analyses of Bone Volume, Trabecular Architecture, and Cell Densities 
To investigate structural and cellular changes occurring within the metaphysis (a region of a long 
bone with active modelling and remodeling most affected by MTX as shown in our previous  
studies [22,25]), one tibia was fixed in 10% formalin for 24 h then decalcified in Immunocal solution 
(Decal Corp., Tallman, NY, USA) over two weeks before being halved longitudinally along the  
midline and processed for paraffin embedding. Sections of 4 μm thickness were obtained, mounted on 
Superfrost™ slides (Thermo Fisher Scientific Australia, Scoresby, VIC, Australia), and stained for 
tartrate-resistant alkaline phosphatase (TRAP) (a marker for osteoclasts) and haematoxylin before being 
examined under a light microscope. To examine treatment effects on bone architecture, bone volume as 
a percentage of tissue volume (BV/TV%), trabecular thickness (Tb.Thk), trabecular spacing (Tb.Spc), 
and trabecular number (Tb.#) were measured in the secondary spongiosa region of metaphysis bone 
using Bio-analysis software as we described [20,22]. In addition, cell numbers/densities were measured 
for TRAP+ osteoclasts and cuboidal osteoblasts lining the trabecular surface in the secondary spongiosa 
(cells/mm2 trabecular area), as well as adipocytes in the lower secondary spongiosa (cells/mm2 bone 
marrow area) as we described [23,25]. 
4.3. Serum Alkaline Phosphotase (ALP) Concentration 
To investigate the effects of MTX, genistein, and the combination (Gen/MTX) treatments on bone 
formation, serum levels of alkaline phosphatase (ALP, a marker of osteoblast differentiation and activity) 
were measured using Konelav 20XT clinical chemistry analyzer (Thermo Scientific, Vantaa, Finland) 
as outlined previously [63]. 
4.4. Ex Vivo Osteoclastogenic Formation 
Ex vivo osteoclast formation was performed as an indicator of treatment effects on the potential  
of the bone marrow precursor cells to form mature osteoclasts. As performed previously [25],  
whole bone marrow flushed from both femurs, the remaining tibia, and both humeri was combined  
and cultured overnight in basal media containing alpha-minimal essential medium (α-MEM)  
(Sigma, Sydney, Australia), 10% fetal calf serum (FCS) (Invitrogen, Carlsbad, CA, USA), 15 mM  
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) (Sigma), 50 μg/mL Pen/Strep (Invitrogen), 
and 130 μM L-ascorbate-2-phosphate (Sigma). At the following day, the non-adherent bone marrow 
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mononuclear cells (BMMNCs) were isolated and seeded at 1 × 106 cells/well into 48-well plates in 
triplicate/treatment and supplemented with macrophage colony stimulating factor (M-CSF) (Peprotech, 
Rocky Hill, NJ, USA). After 24 h, osteoclastogenesis was induced over the following seven days with 
the addition of receptor activator of NF-κB ligand (RANKL) (Peprotech, Rocky Hill, NJ, USA)  
at 30 ng/mL to the culture medium. Osteoclast cultures were then formalin-fixed and stained for TRAP. 
Osteoclasts were then viewed under a light microscope and quantified as TRAP+ multinucleated 
osteoclasts (≥3 nuclei)/mm2 as described [25]. 
4.5. RNA Isolation and RT-PCR Gene Expression Analyses 
Levels of mRNA expression of osteoclastogenesis, osteoblastogenesis, and adipogenesis-related 
genes were examined by RT-PCR using RNA isolated from frozen metaphysis samples, including 
RANKL and OPG, pro-inflammatory cytokines TNF-α, IL-1, and IL-6, osteoblast activity marker 
osteocalcin (OCN) and adipocyte differentiation factor C/EBP-α [24,29]. Using 2 μg RNA, cDNA was 
synthesised using Superscript III (Applied Biosystems, Sydney, Australia). RT-PCR was subsequently 
performed using an Applied Biosystems 7500 Fast Real-Time PCR system (Applied Biosystems, 
Sydney, Australia). Reactions of 20 μL were performed using 100 ng/mL cDNA, and amplification of 
product was measured via SYBR green fluorescence relative to endogenous cyclophilin (CYC) and 
expressed in the comparative Ct format (2−ΔCt). Primer sequences for each gene of interest are provided 
in Table 1 (all primers ordered from Geneworks, Adelaide, Australia). 
Table 1. Forward and reverse primer sequences used for mRNA expression analysis. 
Cyclophilin A (Cyc A), receptor activator of NF-κB ligand (RANKL), osteoprotogerin 
(OPG), tumor necrosis factor-alpha (TNF-α), interleukin-1 beta (IL-1β), interleukin-6 (IL-6), 
and CCAAT/enhanced binding protein-α (C/EBPα). 
Gene Forward Primer (5′–3′) Reverse Primer (5′–3′) 
Cyc A CGTTGGATGGCACGCCTGTG TGCTGGTCTTGCCATTCCTG 
RANKL TGGGCCAAGATCTCTAACATCAC TGGGCCAAGATCTCTAACATCAC 
OPG AGCTGGCACACGAGTGATGAA CACATTCGCACACTCGGTTGT 
TNF-α TGGGCCAAGATCTCTAACATCAC CTCCGCTTGGTGGTTTGCTACGAC
IL-1β GTTTCCCTCCCTGCCTCTGACA GACAATGCTGCCTCGTGACC 
IL-6 GATACCCACAACAGACCAG GCCATTGCACAACTCTTTTCTC 
C/EBPα TCGCCATGCCGGGAGAACTCTAAC CTGGAGGTGGCTGCTCATCGGGG 
4.6. Statistical Analysis 
All statistics analyses were performed using a standard one-way ANOVA with Tukey’s post hoc test 
(using GraphPad Prism 5.01 for Windows, GraphPad Software, San Diego, CA, USA) and data are 
represented as mean ± standard error of the mean (SEM). Significance was set at p < 0.05, where 
significance compared to control group is indicated in the graphs as *, **, and *** representing  
p < 0.05, p < 0.01, and p < 0.001 respectively, and differences between other treatment groups are 
exhibited by symbols “δ” or “#” with significance explained in respective figure legends. 
  




Whilst genistein was found to have a limited ability to significantly protect against MTX-induced 
bone damage in some parameters, genistein supplementation suppressed MTX-induced osteoclast 
formation and showed protective effects on the general health and growth of the MTX-treated animals 
in this acute MTX treatment setting. Future studies are warranted to explore its potential efficacy in 
attenuating MTX chemotherapy-induced bone and bone marrow damages. 
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